SCHEMBL2024652

SCHEMBL2024652

Cc1cc(-c2ccc(C#N)nc2)cc2c1C(=O)N(Cc1ccc(OC(F)(F)F)cc1)C2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 3/20 0.54
PIK3CG P48736 2/20 0.40
CHRM5 P08912 5/20 0.40
TRPA1 O75762 1/20 0.39
ABL1 P00519 1/20 0.39
BRD4 O60885 1/20 0.38
DGKA P23743 2/20 0.36
DGKZ Q13574 2/20 0.36
GRIN2B Q13224 1/20 0.36
GPR6 P46095 1/20 0.35
ALDH1A1 P00352 1/20 0.35
SCN1A P35498 1/20 0.35
SCN4A P35499 1/20 0.35
KCNH2 Q12809 1/20 0.35
SCN5A Q14524 1/20 0.35
SCN9A Q15858 1/20 0.35
SCN2A Q99250 1/20 0.35
SCN3A Q9NY46 1/20 0.35
SCN8A Q9UQD0 1/20 0.35
SCN10A Q9Y5Y9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2028802 0.89 GRM2 (0.57) GRM2PIK3CGCHRM5ABL1GRIN2B
SCHEMBL2023362 0.88 GRM2 (0.57) GRM2PIK3CGCHRM5ABL1GRIN2B
SCHEMBL2027874 0.88 GRM2 (0.56) GRM2PIK3CGCHRM5GRIN2BALDH1A1
SCHEMBL2019500 0.86 GRM2 (0.54) GRM2PIK3CGCHRM5ABL1GRIN2B
SCHEMBL2019548 0.84 GRM2 (0.53) GRM2PIK3CGCHRM5GRIN2BALDH1A1
SCHEMBL2023271 0.84 GRM2 (0.54) GRM2PIK3CGCHRM5ABL1BRD4
SCHEMBL1001737 0.83 GRM2 (0.57) GRM2PIK3CGCHRM5ABL1ALDH1A1
SCHEMBL8270193 0.83 GRM2 (0.57) GRM2PIK3CGCHRM5ABL1KCNH2
SCHEMBL2024575 0.82 GRM2 (0.51) GRM2PIK3CGCHRM5GRIN2B
SCHEMBL2023390 0.82 GRM2 (0.57) GRM2PIK3CGCHRM5GRIN2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2357169-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators AstraZeneca AB (SE) 2011-08-17 EP disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM3 GRM2 4/4885PIK3CG 1735/4885CHRM5 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.